Royalty PharmaRPRX
RPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 89
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,323% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $1.47M
48% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 40
32% more repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 119
29% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 9 (+2) [Q3]
3% more funds holding
Funds holding: 374 [Q2] → 387 (+13) [Q3]
10% less capital invested
Capital invested by funds: $9.7B [Q2] → $8.74B (-$963M) [Q3]
12.48% less ownership
Funds ownership: 81.39% [Q2] → 68.91% (-12.48%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$40
30%
upside
Avg. target
$40
30%
upside
High target
$40
30%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Andrew Baum 25% 1-year accuracy 1 / 4 met price target | 30%upside $40 | Buy Maintained | 25 Oct 2024 |
Financial journalist opinion
Based on 8 articles about RPRX published over the past 30 days
Positive
Zacks Investment Research
15 hours ago
Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know
The mean of analysts' price targets for Royalty Pharma (RPRX) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Seeking Alpha
5 days ago
Royalty Pharma: Key Strategic Updates To Be Priced In
Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating.
Positive
Zacks Investment Research
1 week ago
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 200-day moving average, suggesting a long-term bullish trend.
Positive
Reuters
1 week ago
Royalty Pharma simplifies corporate structure with $1.1 bln deal
Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure.
Neutral
GlobeNewsWire
1 week ago
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be held at 6:45 p.m. Eastern Time / 3:45 p.m. Pacific Time at the 43rd Annual J.P. Morgan Healthcare Conference.
Neutral
GlobeNewsWire
1 week ago
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years Simplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intended to be repurchased in 2025 subject to market conditions Maintain significant capacity for new royalty transactions and remain committed to mid-single digit percentage annual dividend growth and investment grade credit rating Royalty Pharma to host investor call today, Friday, January 10, 2025 at 8:30am ET NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps to enhance shareholder value. First, the Board of Directors has agreed to acquire its external manager, RP Management, LLC (the “Manager”).
Neutral
GlobeNewsWire
1 week ago
Royalty Pharma Announces Dividend Increase
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend.
Positive
Finbold
3 weeks ago
ChatGPT picks 5 stocks to buy for the start of 2025
As we enter the tail end of 2024, which has been a great year for the markets, as the S&P 500 has rallied by 27.35% since the beginning of the year, one question lies on the minds of investors the world over — what do I invest in for next year?
Positive
The Motley Fool
1 month ago
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally. Royalty Pharma (RPRX 0.04%), W.P.
Positive
The Motley Fool
1 month ago
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A couple of overlooked dividend payers offer high yields and reliable dividend payout growth, but you wouldn't know it by looking at their stock prices.
Charts implemented using Lightweight Charts™